References
- Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13:2436–41.
- Ismail A, Ziada H. Sheashaa H, Shehab El-Din A. Decline of viral hepatitis prevalence among asymptomatic Egyptian blood donors: a glimmer of hope. Eur J Intern Med 2009;20:490–3.
- Chen L, Borozan I, Feld J, Sun J, Tannis L, Coltescu C, Heathcote J, Edwards A, McGilvray I. Hepatic gene expression discriminates responders and non-responders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005;128:1437–44.
- Corouge M, Pol S. New treatments for chronic hepatitis C virus infection. Med Mal Infect 2011.[Epub ahead of print].
- Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, Sugiyama M, Matsuura K, Sugauchi F, Asahina Y, Nakagawa M, Watanabe M, Sakamoto M, Maekawa S, Sakai A, Kaneko S, Ito K, Masaki N, Tokunaga K, Izumi N, Mizokami M. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 2011;54:439–48.
- Meurs E, Breiman A. The interferon inducing pathways and the hepatitis C virus. World J Gastroenterol 2007;13:2446–54.
- Kawai T, Akira S. Toll-like receptor and RIG-1-like receptor signaling. Ann N Y Acad Sci 2008;1143:1–20.
- Mezger M, Bonin M, Kessler T, Gebhardt F, Einsele H, Loeffler J. Toll-like receptor 3 has no critical role during early immune response of human monocyte-derived dendritic cells after infection with the human cytomegalovirus strain TB40E. Viral Immunol 2009;22:343–51.
- Vollmer J, Rankin R, Hartmann H, Jurk M, Samulowitz U, Wader T. Immunopharmacology of CpG oligodeoxynucleotides and rivabirin. Antimicrob Agents Chemother 2004;48:2314–7.
- Ishak K. Pathologic features of chronic hepatitis: a review and update. Am J Clin Pathol 2000;113:40–55.
- Ishak K, Baptista A, Bianchi L, Callea F, De Grote J , Gaudat F, Denkg H, Desmeth V, Korbi G, MacSween RNM, Phillips MJ, Portmann BG, Poulsen H, Scheuer PJ, Schmid M, Thaler H. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–9.
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt method. Methods 2001;25:402–8.
- Mozer-Lisewska L, Sluzewski W, Kaczmarek M, Jenek R, Szczepanski M, Figlerowicz M, Kowala-Piaskowska A, Zeromski J. Tissue localization of toll-like receptors in biopsy specimens of liver from children infected with hepatitis C virus. Scand J Immunol 2005;52:407–12.
- Matsumoto M, Funami K, Tanabe M, Oshiumi H, Shingai M, Seto Y, Yamamoto A, Seya T. Subcellular localization of toll-like receptor 3 inhuman dendritic cells. J Immunol 2003;171:3154–62.
- Gale M, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005;436:939–45.
- Kanda T, Imazeki F, Yokosuka O. New antiviral therapies for chronic hepatitis C. Hepatol Int 2010;19:548–61.
- Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxì A, Chaneac M, Reddy KR. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425–33.
- Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140: 346–55.
- Yuki N, Matsumoto S, Kato M, Yamaguchi T. Hepatic Toll-like receptor 3 expression in chronic hepatitis C genotype 1 correlates with treatment response to peginterferon plus ribavirin. J Viral Hepat 2010;17:130–8.
- Honda K, Takaoka A, Taniguchi T. Type I interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006;25:349–60.
- Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005;23:307–36.
- Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, Heim MH. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008;105:7034–9.